Long-Acting HIV Treatment Backed By GSK, Pfizer Scores FDA Approval As Preventative Option

  • The FDA has approved ViiV Healthcare's Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option, to reduce the risk of sexually acquired HIV-1. 
  • The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and have a negative HIV-1 test before initiation. 
  • Related Link: ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi.
  • The approval comes almost a month before the PDUFA date of January 24, 2022
  • ViiV Healthcare is a joint venture between GlaxoSmithKline plc GSKPfizer Inc PFE, and Shionogi.
  • Cabotegravir long-acting for PrEP is provided as an injection given as few as six times per year and is initiated with a single 600 mg (3-ml) injection given one month apart for two consecutive months. 
  • After the second initiation injection, the recommended continuation injection dose is a single 600 mg (3-ml) injection given every two months. 
  • Vocabria (cabotegravir oral tablets) may be administered for approximately one month before initiating the first injection to assess the tolerability of the medicine.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: GSK stock is down 0.21% at $42.97, PFE shares are down 0.20% at $60.90 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsHIVHIV treatment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!